International ME/CFS Conference 2025 to Spotlight Advances in Treatment and Research for Chronic Fatigue and Post-COVID Syndromes

Berlin, Germany — Medical professionals, researchers, and global experts will converge—virtually and in-person—on May 12-13, 2025, for the International ME/CFS Conference, a two-day hybrid event dedicated to the latest developments in the care, treatment, and scientific understanding of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Post-COVID Syndrome (PCS).

Hosted from the Harnack House of the Max Planck Society in Berlin and broadcast online, the conference is free to attend with registration and will be held entirely in English. Participants may earn up to 12 CME credits, awarded by Ärztekammer Berlin.

Led by Prof. Carmen Scheibenbogen, Director of the Division of Immunodeficiencies and Post-infectious Diseases at Charité – University Medicine Berlin, the conference will feature leading international researchers presenting on key disease mechanisms including immune dysregulation, cardiovascular instability, mitochondrial dysfunction, and autoimmunity.

A significant highlight of the conference will be the presentation of recent clinical trial results on Oxaloacetate, a metabolic supplement that has shown notable success in reducing fatigue symptoms in both ME/CFS and Long COVID patients. The findings will be presented by Alan Cash, physicist, entrepreneur, and Chief Science Officer at Terra Biological LLC. Cash’s team has conducted pioneering research on Oxaloacetate’s potential to mimic the effects of calorie restriction and improve cellular energy balance.